Genetic variants in CYP2R1, CYP24A1, and VDR modify the efficacy of vitamin D3 supplementation for increasing serum 25-hydroxyvitamin D levels in a randomized controlled trial.

ABSTRACT:

Context

Adequate serum 25-hydroxyvitamin D concentrations, [25(OH)D], are required for optimal bone health, and low levels are associated with chronic diseases.

Objective

We investigated whether 41 candidate single nucleotide polymorphisms (SNPs) in vitamin D and calcium pathway genes (GC, DHCR7, CYP2R1, CYP27B1, CYP24A1, VDR, and CASR) are associated with [25(OH)D] or modify the increase in [25(OH)D] from vitamin D3 supplementation.

Design and setting

Baseline and year 1 [25(OH)D] measurements from a randomized controlled trial conducted at 11 clinical centers in the United States.

Participants

A total of 1787 healthy non-Hispanic white participants aged 45-75 years.

Interventions

Vitamin D3 (1000 IU/d), calcium carbonate (1200 mg/d elemental), both, or

SUBMITTER: Barry EL 

PROVIDER: S-EPMC4184076 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature